

# Dan Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9440190/publications.pdf>

Version: 2024-02-01

10  
papers

765  
citations

1162367

8  
h-index

1372195

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 704-715.	5.1	272
2	Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1229-1240.	1.1	230
3	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	3.2	77
4	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 399-410.	1.1	69
5	Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. <i>Current Drug Metabolism</i> , 2012, 13, 911-922.	0.7	41
6	Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1216-1230.	2.3	25
7	Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. <i>MAbs</i> , 2020, 12, 1699-768.	2.6	21
8	Strategies to address drug interaction potential for antibody-drug conjugates in clinical development. <i>Bioanalysis</i> , 2013, 5, 1115-1130.	0.6	19
9	Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S105-S119.	1.0	8
10	Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 175-185.	1.1	3